Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial
| Autor: | Malcolm John Stoker, Robert van Seventer, Mark Versavel, James P. Young, Hilary A. Feister, Laurence Rigaudy |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Sleep Wake Disorders medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions Pregabalin Neuralgia Postherpetic Placebo law.invention Placebos Randomized controlled trial Double-Blind Method law medicine Humans Adverse effect gamma-Aminobutyric Acid Aged Aged 80 and over Postherpetic neuralgia business.industry General Medicine Middle Aged medicine.disease Clinical trial Treatment Outcome Tolerability Anesthesia Neuropathic pain Physical therapy Female business medicine.drug |
| Zdroj: | Current medical research and opinion. 22(2) |
| ISSN: | 0300-7995 |
| Popis: | This trial evaluated the efficacy and safety of pregabalin dosed twice daily (BID) for relief of neuro-pathic pain associated with postherpetic neuralgia (PHN).The 13-week, double-blind, placebo-controlled study randomized 370 patients with PHN to pregabalin (150, 300, or 600 mg/day BID) or placebo.Primary efficacy measure was endpoint mean pain score from daily pain diaries. Secondary efficacy measures included endpoint mean sleep-interference score from daily sleep diaries and Patient Global Impression of Change (PGIC). Safety evaluations included adverse events (AEs), physical and neurologic examinations, 12-lead ECG, vital signs, and laboratory testing.Pregabalin provided significant, dose-proportional pain relief at endpoint: difference from placebo in mean pain score, 150 mg/day, -0.88, p = 0.0077; 300 mg/day, -1.07, p = 0.0016; 600 mg/day, -1.79, p = 0.0003. Weekly mean pain scores significantly improved as early as week 1. Sleep interference in all pregabalin groups was also significantly improved at endpoint, compared with placebo (p0.001), beginning at week 1 (p0.01). At study termination, patients in the 150 (p = 0.02) and 600 mg/day (p = 0.003) groups were more likely to report global improvement than were those in the placebo group. Most AEs were mild or moderate. Among pregabalin-treated patients, 13.5% withdrew due to AEs, most commonly for dizziness (16 patients, 5.8%), somnolence (8, 2.9%), or ataxia (7, 2.5%).Pregabalin, dosed BID, reduced neuropathic pain associated with PHN and was well tolerated. It also reduced the extent to which pain interfered with sleep. Pregabalin's effects were seen as early as week 1 and were sustained throughout the 13-week study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|